Code Pharma is preparing to present findings from clinical trials of its HIV drug, GAMMORA, at upcoming international conferences. The presentations will take place at the HIV Drug Therapy 2024 Conference in Glasgow in November 2024, and at the HIV Persistence During Therapy Workshop in Miami, Florida in December 2024.
GAMMORA's Novel Mechanism of Action
GAMMORA represents a new approach to HIV treatment. Unlike current antiretroviral therapies that control the virus by inhibiting its activity, GAMMORA targets and eliminates HIV-infected cells. This is achieved by inducing self-destruction of these cells, which allows the immune system to regenerate healthy CD4 cells. The drug is a synthetic peptide derived from HIV-1 integrase, initially identified at the Hebrew University of Jerusalem, Israel. By inducing the viral integration process, GAMMORA pushes HIV-infected cells into self-destruction.
Early clinical trials have indicated that GAMMORA can significantly reduce the HIV viral load without causing harmful side effects. The drug's precision targeting ensures that only infected cells are eliminated, leaving healthy cells intact. This mechanism offers the potential for a cure, contrasting with the lifelong management of HIV as a chronic condition required by current treatments.
Code Pharma's Focus on Peptide-Based Therapies
Code Pharma, headquartered in the Netherlands with R&D operations in Israel, specializes in developing cost-effective, peptide-based treatments for infectious diseases and cancer. The company collaborates with an international team of experts in peptide chemistry, cell culture, and clinical development. Code Pharma aims to deliver therapies that address unmet medical needs and improve patient outcomes globally.
